Pentraxin-3 Serum Levels Are Associated with Disease Severity and Mortality in Patients with Systemic Inflammatory Response Syndrome

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Bastrup Birk, Simone ^a   Skjoedt, Mikkel Ole ^a   Munthe Fog, Lea ^a   Strom, Jens J ^b   Ma, Ying Jie ^a   Garred, Peter ^a  

^a Rigshospitalet   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PENTRAXIN 3;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEPTIC SHOCK; SEX RATIO; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; SOLID PHASE ENZYME LINKED IMMUNOSORBENT ASSAY; SURVIVAL PREDICTION; SURVIVAL TIME; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECOMBINANT PROTEINS; REFERENCE VALUES; ROC CURVE; SEPSIS; SERUM AMYLOID P-COMPONENT; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; YOUNG ADULT;

EID: 84883634419     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073119     Document Type: Article

References (31)

1. Garlanda C, Bottazzi B, Bastone A, Mantovani A, (2005) Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 23: 337-366.
2. Inforzato A, Jaillon S, Moalli F, Barbati E, Bonavita E, et al. (2011) The long pentraxin PTX3 at the crossroads between innate immunity and tissue remodelling. Tissue Antigens 77: 271-282.
3. Inforzato A, Bottazzi B, Garlanda C, Valentino S, Mantovani A, (2012) Pentraxins in humoral innate immunity. Adv Exp Med Biol 946: 1-20.
4. Agrawal A, Singh PP, Bottazzi B, Garlanda C, Mantovani A, (2009) Pattern recognition by pentraxins. Adv Exp Med Biol 653: 98-116.
5. Jaillon S, Peri G, Delneste Y, Fremaux I, Doni A, et al. (2007) The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 204: 793-804.
6. Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, et al. (2009) Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med 47: 471-477.
7. Bottazzi B, Doni A, Garlanda C, Mantovani A, (2010) An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 28: 157-183.
8. Mantovani A, Garlanda C, Doni A, Bottazzi B, (2008) Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol 28: 1-13.
9. Doni A, Garlanda C, Bottazzi B, Meri S, Garred P, et al. (2012) Interactions of the humoral pattern recognition molecule PTX3 with the complement system. Immunobiology 217: 1122-1128.
10. Guo T, Ke L, Qi B, Wan J, Ge J, et al. (2012) PTX3 is located at the membrane of late apoptotic macrophages and mediates the phagocytosis of macrophages. J Clin Immunol 32: 330-339.
11. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, et al. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31: 1250-1256.
12. Brun-Buisson C, (2000) The epidemiology of the systemic inflammatory response. Intensive Care Med 26Suppl 1: S64-S74.
13. Martin GS, (2012) Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther 10: 701-706.
14. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, et al. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310.
15. Claus RA, Otto GP, Deigner HP, Bauer M, (2010) Approaching clinical reality: markers for monitoring systemic inflammation and sepsis. Curr Mol Med 10: 227-235.
16. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, et al. (2007) Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 27: 161-167.
17. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, et al. (2004) Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110: 2349-2354.
18. Muller B, Peri G, Doni A, Torri V, Landmann R, et al. (2001) Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 29: 1404-1407.
19. Huttunen R, Hurme M, Aittoniemi J, Huhtala H, Vuento R, et al. (2011) High plasma level of long pentraxin 3 (PTX3) is associated with fatal disease in bacteremic patients: a prospective cohort study. PLoS One 6: e17653.
20. Mauri T, Bellani G, Patroniti N, Coppadoro A, Peri G, et al. (2010) Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med 36: 621-629.
21. Uusitalo-Seppala R, Huttunen R, Aittoniemi J, Koskinen P, Leino A, et al. (2013) Pentraxin 3 (PTX3) is associated with severe sepsis and fatal disease in emergency room patients with suspected infection: a prospective cohort study. PLoS One 8: e53661.
22. Bottazzi B, Vouret-Craviari V, Bastone A, De GL, Matteucci C, et al. (1997) Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 272: 32817-32823.
23. Libby P Ridker PM, (2004) Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 116Suppl 6A: 9S-16S.
24. Kastrup J, (2012) Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology 217: 483-491.
25. Thuno M, Macho B, Eugen-Olsen J, (2009) suPAR: the molecular crystal ball. Dis Markers 27: 157-172.
26. Garred P, Strom J, Quist L, Taaning E, Madsen HO, (2003) Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis 188: 1394-1403.
27. Kornblit B, Munthe-Fog L, Madsen HO, Strom J, Vindelov L, et al. (2008) Association of HMGB1 polymorphisms with outcome in patients with systemic inflammatory response syndrome. Crit Care 12: R83.
28. Le GallJR, Lemeshow S, Saulnier F, (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270: 2957-2963.
29. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, et al. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644-1655.
30. Hummelshoj T, Thielens NM, Madsen HO, Arlaud GJ, Sim RB, et al. (2007) Molecular organization of human Ficolin-2. Mol Immunol 44: 401-411.
31. Kohler G Milstein C, (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497.